Analysts at StockNews.com started coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Bellicum Pharmaceuticals Trading Down 6.6 % NASDAQ:BLCM opened at $0.07 on Tuesday. Bellicum Pharmaceuticals has a one year low of […] Read this story
